Merck Serono Appoints Luciano Rossetti
News Jul 17, 2014
Merck Serono has announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
In his most recent role Rossetti (57) acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas.
At MSD, he played a key role in shaping and implementing the development strategy of several potential compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Before joining MSD in 2006, Rossetti was an internationally recognized academic scientist for 18 years.
“I’m thrilled to welcome Luciano Rossetti to Merck,” said Belén Garijo, President and CEO at Merck Serono. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.”
Rossetti will be based in Billerica, outside Boston, Massachusetts (U.S.), and share his time between Merck’s headquarters in Darmstadt (Germany) and Billerica - one of Merck Serono’s four global R&D hubs.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE